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Abstract: Ion homeostasis is crucial for organism functioning, and its alterations may cause diseases.
For example, copper insufficiency and overload are associated with Menkes and Wilson’s diseases,
respectively, and iron imbalance is observed in Parkinson’s and Alzheimer’s diseases. To better un-
derstand human diseases, Saccharomyces cerevisiae yeast are used as a model organism. In our studies,
we used the vps13∆ yeast strain as a model of rare neurological diseases caused by mutations in
VPS13A–D genes. In this work, we show that overexpression of genes encoding copper transporters,
CTR1, CTR3, and CCC2, or the addition of copper salt to the medium, improved functioning of the
vps13∆ mutant. We show that their mechanism of action, at least partially, depends on increasing iron
content in the cells by the copper-dependent iron uptake system. Finally, we present that treatment
with copper ionophores, disulfiram, elesclomol, and sodium pyrithione, also resulted in alleviation of
the defects observed in vps13∆ cells. Our study points at copper and iron homeostasis as a potential
therapeutic target for further investigation in higher eukaryotic models of VPS13-related diseases.
Keywords: yeast model; neurodegeneration; VPS13; CTR1; CCC2; FET3; disulfiram; elesclomol;
pyrithione; copper homeostasis
1. Introduction
Copper is a trace element essential for human health. It regulates the activity of many
enzymes, called cuproenzymes, in which it serves as a cofactor or allosteric regulator [1].
Cuproenzymes facilitate various reactions that are important for cellular respiration, ox-
idative stress defence, iron oxidation, melanin synthesis, connective tissue maturation,
blood clotting, and lipid metabolism [1–3]. Copper is also crucial for nervous system
functioning where it is involved in neurotransmission [3]. Lastly, copper binds to the
transcription factors and regulates gene expression, mostly involved in copper storage
and buffering [1]. To maintain copper physiological levels, copper homeostasis is tightly
regulated [4]. Its alterations are often linked with various diseases. Disturbances may
result from nutrition-related causes, but also impaired ion homeostasis regulation, which
could have a genetic background. For example, mutations in the ATP7A gene, encoding
a copper transporter responsible for copper transport from enterocytes to blood, lead
to copper deficiency and development of Menkes disease characterised by progressive
neurodegeneration and connective tissue disturbances [5]. Genetic inactivation of ATP7B,
an ATP7A paralog encoding copper transporter responsible for removing copper excess
from the liver to bile, results in copper overload and development of Wilson’s disease, pri-
marily manifesting in liver function impairment [5]. While the disease progresses, copper
accumulates in other organs, including the brain, which may cause neurodegeneration [5].
Moreover, copper is also linked with neurodegenerative diseases with protein aggregation.
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Copper interacts with the amyloid precursor protein, its peptide derivatives and hunt-
ingtin, which are involved in Alzheimer’s and Huntington’s diseases, respectively [3]. It
is suggested that this interaction mediates protein aggregation and contributes to disease
development [3]. Moreover, metals found in synapses, including copper, contribute to
α-synuclein aggregation, a hallmark of Parkinson’s disease [6]. Therefore, copper could be
a potential factor important for disease progression [6]. On the other hand, copper levels
are reduced in the affected brain regions of Parkinson’s disease patients [6]. This shows
that function of copper in the brain and its contribution to neurodegenerative diseases is
not fully elucidated. To investigate these diseases and to better understand their molecular
pathologies, research on laboratory models, including yeast, were carried out.
Saccharomyces cerevisiae yeast is a unicellular organism commonly used in research
regarding genetics, cell, and molecular biology. This is based on the fact that processes
crucial for proper cellular functioning are conserved from yeast to humans. Therefore,
it is possible to use yeast for studying human diseases. Yeast models of Parkinson’s,
Alzheimer’s, and Huntington’s diseases have been developed [7,8]. In these models,
respective protein aggregates are produced and then their impact on cell functioning
is investigated. Most importantly, some findings from research on yeast models were
confirmed in mammalian cell lines [9,10], which shows yeast usefulness in studies on
candidate therapeutic targets and drugs. Moreover, many human genes complement gene
deletions in yeast [11], which allows for the use of yeast as a platform for studying the
effects of disease-causing mutations. Examples are human ATP7A and ATP7B, human
homologues of the yeast CCC2 gene [12]. CCC2 encodes an ATPase, which transports
copper to the Golgi apparatus [13,14]. The cDNA of ATP7A and ATP7B complements CCC2
deletion [15–18], and the yeast system is used to study pathogenic mutations in ATP7A and
ATP7B [19–22]. Lastly, ion regulation is well characterised in yeast [23]; therefore, yeast
could be used for studying disturbances of ion homeostasis including copper homeostasis.
In yeast, copper enters the cell mainly via Ctr1 or Ctr3 plasma membrane copper trans-
porters [24–26]. However, due to the Ty2 transposon insertion in the CTR3 promoter region,
CTR3 expression is abolished in S288C-derived laboratory strains including BY4741 [27].
Alternative copper uptake routes using non-specific transporters were also described and
are mostly utilised in copper-rich environment, which causes Ctr1 degradation [23,28,29].
Copper is redox active metal, and it can be used in various redox reactions important for
cellular physiology. For example, it is involved in iron import. Copper is a cofactor in Fet3
oxidase, which, together with Ftr1 permease, comprises a high-affinity iron uptake system
in yeast cells, crucial for growth in iron limited conditions [30,31]. In this system, Fet3
oxidises ferrous ions (Fe2+) to ferric ions (Fe3+) that are subsequently transported across
the plasma membrane [30,32]. Before targeting to the plasma membrane, Fet3 is loaded
with copper in the Golgi apparatus [13,14,30]. For that, Ccc2 ATPase is required [13,14]. In
addition to the role in iron uptake, copper is also essential for cellular respiration, because
it facilitates electron transport in cytochrome c oxidase, the last enzyme of mitochondrial
respiratory electron transport chain [33]. Finally, copper is also a cofactor of superoxide
dismutase 1 (Sod1), a component of the yeast defence system against reactive oxygen
species [34].
In our research, we used a yeast model of rare, neurological diseases associated with
mutations in human VSP13 genes. There are four human homologs (VPS13A–D) [35], and
mutations in these genes result in chorea-acanthocytosis (ChAc) (VPS13A) [36–38], Cohen’s
syndrome (VPS13B) [39], early-onset parkinsonism (VPS13C) [40] and childhood-onset
movement disorder (VPS13D) [41,42]. Molecular pathogenesis of these diseases is not
understood and no effective treatment is available for the patients. In yeast, one VPS13
homolog is present. Originally, it was identified as a gene encoding protein involved in
vacuolar protein sorting (VPS, origin of the name) [43–45]. Other studies showed its involve-
ment in autophagy [46,47], mitochondrial DNA maintenance [47], sporulation [44,48,49],
endocytosis [50,51], actin cytoskeleton organization [50] and calcium signalling [51]. Re-
cently, Vps13 proteins have also been shown to localise, both in yeast and mammalian
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cell lines, at membrane contact sites (MCS) [47,52–54]. MCS are zones of close proximity
between different organelles or between organelles and the plasma membrane, which
enable direct exchange of lipids and small molecules [55]. At MCS, Vps13 protein most
likely maintains lipid transport between organelles, since it acts as a lipid transfer protein
in in vitro studies and structure of its N-terminal part is predisposed for lipid channelling
between membranes [53,56].
Recently, we showed that vps13 mutant cells are hypersensitive to sodium dodecyl
sulphate (SDS), and this phenotype could be used for genetic and chemical suppressors
screening [51,57]. Identified suppressors were further analysed to define their mechanisms
of action. In this manner, we found that calcineurin downregulation by a MYO3 gene
fragment or FK506 inhibitor overcomes defects observed in the vps13∆ strain [51]. We also
described flavonoids as a group of compounds which mitigate vps13∆ growth defect [57].
Finally, we showed that the FET4 gene, encoding a low-affinity and low-specificity iron
transporter [58–60], is a multicopy suppressor of vps13∆, and that iron is important for
yeast growth in the presence of SDS [57].
In this work, we present the CTR3 gene, encoding plasma membrane copper trans-
porter, as one of the suppressors isolated in our multicopy suppressor screen. We also tested
the CTR1 and CCC2 genes and found that they also acted as suppressors of vps13∆. We
propose that their mechanism of action in vps13∆ relies on increasing the intracellular iron
content via the copper-dependent high-affinity iron uptake system. Finally, we identified
three copper ionophores, disulfiram, elesclomol, and sodium pyrithione, as compounds
alleviating vps13∆ growth defect. These findings show that copper homeostasis and its
relevance for iron uptake is an interesting area for further studies in cell lines and higher
organism models of VPS13-related diseases.
2. Results
2.1. Overexpression of CTR1 and CTR3 Genes and Copper Salts Addition Suppress the
SDS-Hypersensitivity of vps13∆ Cells
In our previous research, we discovered an SDS-hypersensitivity growth phenotype
of vps13∆ mutant and used it to screen for multicopy suppressors [51,57]. One of the
identified genes that improved vps13∆ growth was CTR3 (Figure 1a), which encodes a
plasma membrane copper transporter [26]. Suppressing plasmid isolated from the pFL-44
genomic bank [61] did not contain Ty2 transposon [27]; therefore, we assumed that CTR3
expression occurs when CTR3 was expressed from used vectors. To analyse if suppression
is caused by copper uptake or by Ctr3 protein, per se, we checked the CTR1 gene, encoding
the other plasma membrane copper transporter [24]. It also acted as a vps13∆ suppressor
when overexpressed (Figure 1a). This shows that suppression is related to copper import,
not a particular transporter, and further in this study we used CTR1 as the suppressing
gene. To test if copper is important for the suppression, we performed an assay in which
vps13∆ cells were spread onto YPD + SDS plates (see Materials and Methods), and copper
sulphate or copper chloride were applied on the filters placed on the media surface. We
observed a growth zones around the filters, which indicate that suppression of vps13∆
could also be achieved by treatment with copper salts (Figure 1b). To test if the growth
zones were caused by copper cations, not by sulphate or chloride anions, we also checked
the impact of magnesium sulphate or magnesium chloride on vps13∆ mutant growth. No
growth zones were observed around filters with magnesium sulphate and magnesium
chloride (Figure 1b). To conclude, these results suggest that increasing copper uptake helps
to overcome SDS toxicity in vps13∆ cells.
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Figure 1. SDS-hypersensitivity phenotype of vps13∆ is suppressed by the overexpression of the CTR1 or CTR3 genes,
encoding copper transporters, and by the addition of copper salts. (a) Growth of wild type (WT) and vps13∆ strains bearing
plasmids with CTR1 or CTR3 genes or with empty vector ([-]) was compared by a drop test on plates with YPD and YPD
+ SDS media. (b) The vps13∆ strain was spread onto plate with YPD + SDS media and 2 µL of 1 mM solutions of copper
sulphate (CuSO4), copper chloride (CuCl2), magnesium sulphate (MgSO4) and magnesium chloride (MgCl2) were spotted
on the filter papers. Water was used as a negative control.
2.2. Ctr1–GFP Degradation Is Increased in vps13∆ but vps13∆ Growth Defect Is Not Caused by
Copper Deficiency
Suppression of vps13∆ SDS-hypersensitivity by overexpression of genes encoding
copper transporters or by copper salts addition may suggest defective copper uptake,
which could be caused by impaired action of the Ctr1 in vps13∆ cells. We checked if Ctr1
functioning was altered in vps13∆. Firstly, we examined Ctr1 localisation in wild type and
vps13∆ strains. For that, we tagged the genomic CTR1 gene with a GFP, to produce the
Ctr1–GFP protein. In both strains, the GFP signal was detected on the periphery of the
cell, suggesting that targeting of Ctr1–GFP to the plasma membrane was not disturbed
(Figure 2a). However, we observed cells with a strong GFP signal located in vacuole,
stained by the vacuolar marker CMAC (7-amino-4-chloromethylcoumarin), in vps13∆ but
not in the wild type strain (Figure 2a). This may suggest impaired trafficking, increased
turnover or degradation of Ctr1–GFP in vps13∆ cells. Next, protein extracts from the wild
type and vps13∆ cells producing Ctr1–GFP were analysed by the western blot technique
using the anti-GFP antibody. Several bands of different molecular weight were detected
(Figure 2b), but no band corresponding to protein of predicted molecular weight of Ctr1–
GFP (71 kDa) was found. However, in a previous study, a Ctr1–HA protein was shown to
migrate in SDS polyacrylamide gel as protein of molecular weight of about 100–105 kDa
instead of the predicted 46 kDa [25]. This difference is explained by the heavy glycosylation
of Ctr1 [25]. Taking this into account, the band of molecular weight of approximately
130 kDa was likely a full length Ctr1–GFP (Figure 2b). Other bands in the blot were probably
products of Ctr1–GFP degradation including the lowest band corresponding to a molecular
weight of about 27 kDa, which was most likely free GFP (Figure 2b). Quantification of
western blot analysis showed that the level of Ctr1–GFP was lower in vps13∆ cells; however,
the observed differences were not statistically significant (Figure 2c). Nevertheless, we
found significant changes in the levels of degradation products (Figure 2b,c). In vps13∆, the
level of one of the degradation product (marked as deg1) and free GFP were, respectively,
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significantly lower and higher comparing with the wild type strain (Figure 2b,c). The
elevated level of the free GFP (Figure 2b,c) corresponded with the strong GFP signal in
vacuoles in vps13∆ cells (Figure 2a). Because Ctr1–GFP is degraded in the vacuole [29], our
results suggest an increased vacuolar degradation of Ctr1–GFP in the vps13∆ strain.
Figure 2. Degradation of Ctr1–GFP and copper level are increased in vps13∆. (a) Fluorescence microscopy images of wild
type and vps13∆ cells with GFP-tagged Ctr1 protein. Vacuoles were stained with CMAC. Scale bar 5 µm. (b) Western blot
analysis of protein extracts obtained from wild type and vps13∆ cells with GFP-tagged Ctr1 protein. Anti-GFP antibody was
used for protein detection. Extract from yeast cells without GFP tag was used as a negative control (marked as control).
Phosphoglycerate kinase 1 (Pgk1), detected with anti-Pgk1 antibody, was used as a loading control. (c) Quantification of
western blot results. Relative levels of Ctr1–GFP, deg1, and GFP (in relation to Pgk1) are shown. Mean of the measurements
for Ctr1–GFP in wild type cells was set to 1. Results were analysed by two-tailed Student’s t-test (n = 3, ns p > 0.05, * p < 0.05,
** p < 0.01). Error bars represent SD. (d) Copper levels measurement in WT[-], vps13∆[-], vps13∆[CTR1] and ctr1∆[-] strains.
Yeast were cultivated in YPD + CuSO4 media. Copper content was measured by ICP-AES. Obtained results were analysed
by ANOVA followed by Tukey’s multiple comparison test (n = 3, * p < 0.05, *** p < 0.001).
Changes observed in the Ctr1–GFP processing in vps13∆ cells may result in lowered
copper levels. To verify this hypothesis, we measured copper levels in cells of the wild
type, vps13∆, vps13∆ overexpressing CTR1 gene and ctr1∆ serving as a negative control.
For that, we used inductively coupled plasma atomic emission spectroscopy (ICP-AES)
technique. We were not able to determine copper levels when yeast were cultivated
in YPD media, because the measurement results were below the detection point (not
shown). To overcome this, we supplemented YPD media with copper sulphate. When YPD
medium was supplemented with copper sulphate, the copper level in vps13∆ was slightly
elevated in comparison to the wild type strain (Figure 2d). This may suggest a higher
demand for copper in vps13∆ cells. Overexpression of the CTR1 gene increased copper level
approximately two-fold in vps13∆ (Figure 2d), which shows that CTR1 most likely improves
vps13∆ growth by increasing intracellular copper. However, the endogenously encoded
Ctr1 was not involved in copper import to the yeast cells in tested conditions, because
copper levels were comparable in the wild type and ctr1∆ cells (Figure 2d). This result was
expected, because in copper-rich conditions copper uptake is mediated not by Ctr1 but
Int. J. Mol. Sci. 2021, 22, 2248 6 of 25
rather non-specific transporters, since Ctr1 is degraded when copper is abundant [28,29].
Therefore, it is still possible that Ctr1 functioning is impaired in the vps13∆ cells, resulting in
copper deficiency when copper uptake in yeast cells is mediated by endogenously encoded
Ctr1. To address this possibility, we compared the growth of the wild type, vps13∆ and
ctr1∆ strains on the media with bathocuproinedisulfonic acid disodium salt (BPS), a copper
chelator, which limits copper bioavailability. Only the ctr1∆ strain was sensitive to BPS
addition, and the growth of the wild type and vps13∆ strains was comparable (Figure A1a).
This result shows that Ctr1 functioning is most likely not impaired in vps13∆ cells.
The fact that copper levels in vps13∆ cells were not lowered but slightly elevated
compared to wild type in copper-rich media prompted us to check if vps13∆ is still more
sensitive to SDS upon copper supplementation. We compared the growth of the wild type
and vps13∆ cells on YPD + SDS plates with and without copper sulphate addition. Growth
of both strains was improved by copper sulphate but vps13∆ was still more sensitive to SDS
than the wild type (Figure A1b). This result suggests that the vps13∆ SDS-hypersensitivity
is not caused by copper deficiency. Moreover, copper sulphate improved the growth of the
wild type strain, which shows that the suppression is not specific to the vps13∆. We found
also that CTR1 overexpression reduces SDS sensitivity of the wild type strain (Figure A1c).
To conclude, we observed changes in Ctr1–GFP processing indicating its increased
degradation in vps13∆ cells. We presented that CTR1 overexpression increases copper
content in vps13∆ cells. The fact that vps13∆ is not sensitive to BPS addition suggest that
Ctr1 functioning is not impaired in vps13∆ and increased degradation of Ctr1–GFP does not
result in copper deficiency. Therefore, the copper-based suppression of vps13∆ probably
acts by increasing cellular copper level but not by compensation of copper deficiency.
2.3. Copper-Dependent High-Affinity Iron Uptake System Is Required for CTR1 Suppression of
vps13∆ SDS-Hypersensitivity Phenotype
In our recent study [57], we showed the importance of iron for yeast growth on media
with SDS addition. We identified the FET4 gene, encoding low-affinity iron transporter of
plasma membrane, as a multicopy suppressor of vps13∆. The addition of iron salts also
improved growth of vps13∆. Moreover, we showed that some yeast mutants defective in
iron import are hypersensitive to SDS [57]. Importance of iron for vps13∆ growth on SDS
media prompted us to check, if increasing copper uptake suppresses vps13∆ by increasing
iron content in cells. This hypothesis is plausible due to the fact that copper is a cofactor
of Fet3 oxidase, a component of the high-affinity iron uptake system. Copper excess
caused by CTR1 overexpression could improve loading of Fet3 with copper, therefore
increasing iron import in vps13∆ cells. Moreover, it was shown previously that copper
supplementation resulted in iron increase in yeast cells [14,62]. This supports the idea of
increased copper-dependent iron uptake as a potential suppression mechanism of vps13∆
by CTR1.
To test our hypothesis, firstly we checked whether the FET3 and CCC2 genes, encoding
the Fet3 oxidase and Ccc2 copper transporter essential for loading of Fet3 with copper,
respectively, were required for CTR1-based suppression of vps13∆. We overexpressed CTR1
in the ccc2∆ vps13∆ and fet3∆ vps13∆ strains and tested their growth. Both ccc2∆ vps13∆
and fet3∆ vps13∆ were more sensitive to SDS than vps13∆, and CTR1 overexpression
did not improve the growth of any of these strains (Figure 3a). This result shows that
the high-affinity iron uptake system is required for CTR1-based suppression. Moreover,
we observed a slight toxicity caused by CTR1 overexpression in the double mutants
(Figure 3a). Next, we overexpressed the CCC2 gene in vps13∆ cells to check if increased
copper import to the Golgi apparatus, potentially increasing Fet3 efficiency, also improves
vps13∆ growth. Indeed, CCC2 overexpression suppressed vps13∆ but not fet3∆ vps13∆
(Figure 3b). This suggests that copper ions need to be transported to the Golgi apparatus in
order to suppress vps13∆, where most likely they are incorporated into the Fet3 oxidase
apoenzyme to increase its activity and, therefore, iron uptake.
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Figure 3. Copper-based suppression of vps13∆ SDS-hypersensitivity acts via a high-affinity iron uptake system to increase
the iron level in vps13∆. (a) Growth of wild type, vps13∆, ccc2∆ vps13∆, and fet3∆ vps13∆ strains bearing plasmid with
CTR1 gene or empty vector was compared by drop test on plates with YPD and YPD + SDS media. (b) Growth of wild
type, vps13∆ and fet3∆ vps13∆ strains bearing plasmid with the CCC2 gene or empty vector was compared by a drop test on
plates with YPD and YPD + SDS media. (c) Iron levels in WT[-], vps13∆[-], vps13∆[CTR1], vps13∆[CTR1], vps13∆[CCC2] and
fet3∆[-] (negative control) strains. Iron content was measured in cells of tested strains by ICP-AES. Obtained result were
analysed by two-tailed Student’s t-test (n = 4, * p < 0.05, ** p < 0.01, *** p < 0.001). Error bars represent SD. Axes are different
in panels of c, indicated by red circles on the same position (20) on the scale.
To test if overexpression of CTR1 or CCC2, or copper supplementation, increased iron
uptake, we performed ICP-AES measurements of iron content in wild type and vps13∆
cells bearing empty vector or plasmid expressing CTR1 or CCC2 genes that were grown in
media with or without copper addition. The fet3∆ strain was used as a negative control [30].
The analysis showed that the iron level was lower in vps13∆ compared with the wild type,
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and it significantly increased upon CTR1 overexpression in vps13∆ (Figure 3c, left panel).
We observed also a slight increase in iron content when CCC2 was overexpressed; however,
the difference did not cross the statistical significance threshold (p = 0.066) (Figure 3c, left
panel). Supplementation with copper greatly increased iron content in all tested strains,
except fet3∆ where the iron level was the lowest in both tested conditions (Figure 3c,
compare left and right panels, note that the scales on y-axes are different). Interestingly, the
difference in iron levels between the wild type and vps13∆ in copper supplemented media
was much higher than without copper supplementation: in YPD media, the iron level in
vps13∆ was 74% of the wild type’s iron level, when in YPD + CuSO4 media, it was only
45% (Figure 3c, right panel), suggesting a disturbed copper and iron homeostasis. A slight
but statistically significant increase in iron content in vps13∆ was observed when CTR1 or
CCC2 were overexpressed in yeast grown in YPD + CuSO4 media (Figure 3c, right panel).
Copper supplementation increased iron content also in the wild type cells, which is in line
with the fact that copper sulphate improved the growth of wild type strain on YPD + SDS
plates (Figure A1b).
To conclude this part, ICP-AES measurements showed a lower iron level in vps13∆
and that copper addition, overexpression of CTR1, and to some extent CCC2, caused its
increase. These data, supported by genetic experiments showing requirement of CCC2 and
FET3 for suppression of vps13∆ by CTR1 (Figure 3a) and by our previous results regarding
importance of iron for the growth on YPD + SDS [57], indicate that increasing iron content
in vps13∆ cells is a likely mechanisms of copper-based suppression of vps13∆.
2.4. Cellular Localisation of Fet3–GFP and Ccc2–GFP Proteins Is Not Altered, but Their Levels
Are Increased in vps13∆ Cells
Requirement for CCC2 and FET3 genes for the suppression of vps13∆ by CTR1 overex-
pression, as well as lower iron level in vps13∆, suggest that the high-affinity iron uptake
system may be partially impaired in vps13∆ cells. Thus, we checked the functioning of
Ccc2 and Fet3 proteins in the vps13∆ mutant. For that, we created strains with genom-
ically encoded Ccc2 and Fet3 proteins tagged with GFP fluorescent marker. Firstly, we
investigated Ccc2–GFP localisation in wild type and vps13∆ cells. To observe if Ccc2–GFP
localises to the Golgi apparatus as shown before [14,63], we transformed yeast with plas-
mid expressing a gene encoding Sec7 tagged with RFP, a marker of the Golgi apparatus
late compartments. Colocalisation of GFP and RPF signals was observed in wild type
and vps13∆ cells (Figure 4a), indicating that Ccc2 was delivered to the Golgi apparatus in
both strains. Next, we investigated the level of Ccc2–GFP. Extracts from yeast producing
Ccc2–GFP were analysed by the western blot technique using an anti-GFP antibody. We
observed a band corresponding to the predicted molecular weight of Ccc2–GFP (137 kDa),
and quantification revealed that the Ccc2–GFP level was significantly higher in vps13∆
cells compared to the wild type (Figure 4b,c). Increased Ccc2–GFP level in vps13∆ cells
may indicate increased demand for copper in the Golgi apparatus.
Similarly, we analysed cells with GFP-tagged Fet3 protein. Fluorescence microscopy
images showed that—in both wild type and vps13∆ cells—Fet3–GFP was targeted to the
periphery of cells, suggesting plasma membrane localisation (Figure 4d). In western blot
analysis of protein extracts from Fet3–GFP producing strains, we observed the band of
a molecular weight of approximately 150 kDa (Figure 4e). In previous studies, the Fet3
protein was shown to migrate in SDS polyacrylamide gel as a protein of molecular weight
of about 120 kDa [13,14], instead of the predicted 72 kDa. This difference, alike for Ctr1, is
explained by the glycosylation of Fet3 [13,14]. Therefore, the observed band in our western
blot is most likely Fet3–GFP (Figure 4e). Quantification of the western blot results showed
that Fet3–GFP level is also increased in vps13∆ (Figure 4f), comparable to Ccc2–GFP.
To summarise, our results show that the localisation of Ccc2–GFP and Fet3–GFP was
properly maintained in vps13∆ cells, since both proteins were found at sites of their action.
However, the levels of both proteins were increased in vps13∆. This may suggest greater
demand for iron in vps13∆.
Int. J. Mol. Sci. 2021, 22, 2248 9 of 25
Figure 4. Impact of VPS13 deletion on Ccc2–GFP and Fet3–GFP localisations and levels. (a,d) Flu-
orescence microscopy images of wild type and vps13∆ cells with GFP-tagged Ccc2 (a) and Fet3
(d) proteins. The Sec7–RFP protein was used as a Golgi apparatus marker in Ccc2–GFP visualisation.
To maintain the same cultivating conditions, strains with GFP-tagged Fet3 used for microscopic obser-
vations were transformed with empty vectors. Scale bar 5 µm. (b,e) Western blot analysis of protein
extracts obtained from yeast with GFP-tagged Ccc2 (b) and Fet3 (e) proteins. Like in microscopic
observations, strains were transformed with empty vector. Anti-GFP antibody was used for protein
detection. Pgk1, detected with anti-Pgk1 antibody, was used as a loading control. Extract from yeast
cells without GFP tag was used as a negative control (marked as control). (c,f) Quantification of
western blot results. Relative levels of Ccc2–GFP (c) and Fet3–GFP (f) (in relation to Pgk1) are shown.
Results were analysed by two-tailed Student’s t-test (for Ccc2–GFP: n = 3 and for Fet3–GFP: n = 7;
* p < 0.05, *** p < 0.001). Error bars represent SD.
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2.5. Copper Ionophores Are Suppressors of vps13∆
Recently, we performed a screen of the Prestwick Chemical Library to find substances
that suppress the vps13∆ SDS-hypersensitivity phenotype [57]. Based on the screen results
and literature, we selected seven compounds that were active in vps13∆ cells. Two of
them, luteolin and tolcapone, were described in our previous report [57]. The other three
identified compounds were copper ionophores, one of which belongs to the library.
The copper ionophore which origins from the Prestwick library was disulfiram
(Figure 5), a drug originally used in treatment of alcoholism and currently gaining in-
terest as a potential anticancer drug with several clinical trials ongoing [64]. The anticancer
activity of disulfiram depends on its ability to increase intracellular copper content in
cancer cells [65–69]. Disulfiram improved cytochrome c oxidase activity in models of
Menkes disease [70] and was also shown to rescue respiratory growth defects related to
copper deficiency in yeast [71].
Figure 5. Copper ionophores suppress several phenotypes of vps13∆. The vps13∆ mutant cells were
spread onto the plates with respective media and tested substances were spotted on the filter papers.
The order of the substances and concentrations used are indicated. Dimethyl sulfoxide (DMSO) was
used as a negative control.
The next tested copper ionophore, which we selected after performing the screen,
was elesclomol (Figure 5), an anticancer candidate drug [72–78] that increases intracellular
copper content with high selectivity to mitochondria [79,80] and targets electron transport
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chain [81,82]. It was also shown to rescue defects observed in various copper deficiency
models, including Menkes disease model [80,83].
The last selected copper ionophore was a sodium salt of pyrithione (Figure 5). A
different pyrithione salt, zinc pyrithione, is an antimicrobial agent that inhibits yeast
growth through copper influx [84]. It was proposed that the pyrithione salt dissociates,
forms complex with extracellular copper and then enters cells [84]. We used sodium salt of
pyrithione, which is less toxic to yeast [84]. Moreover, zinc chloride was highly toxic to
yeast on YPD + SDS medium (our unpublished results); therefore, we wanted to avoid zinc
salts in our experiments. Sodium pyrithione was also shown to improve mitochondrial
ATP synthase activity in models of ATP synthase deficiencies by targeting mitochondrial
protein import [85].
All three copper ionophores improved growth of vps13∆ cells (Figure 5). However,
the sizes of the growth zones were different for all the drugs, indicating different activities
with elesclomol yielding the biggest growth zone at the lowest concentration. Moreover,
suppression by the copper ionophores was not limited to SDS-hypersensitivity phenotype
only. We tested two other growth phenotypes of vps13∆, which we described previously:
cadmium hypersensitivity [57] and canavanine hypersensitivity, implying a defect of endo-
cytosis in vps13∆ [50]. All copper ionophores were active when tested for the reversing
growth defect of vps13∆ cells on medium with cadmium (Figure 5) [57], whereas elesclo-
mol was the only compound that improved vps13∆ growth on medium with canavanine
(Figure 5) [50]. We also checked if CTR1 overexpression suppresses vps13∆ hypersensitiv-
ity to cadmium and canavanine. The vps13∆ growth on media with cadmium addition
was improved upon CTR1 overexpression (Figure A2, left panel). For the canavanine
hypersensitivity phenotype, vps13∆ suppression by CTR1 was very weak (Figure A2, right
panel). These results show that suppression of vps13∆ with copper ionophores or CTR1
overexpression is not specific to SDS, but more general.
2.6. Copper Sulphate and Elesclomol Require FET3, but Not CCC2, for vps13∆ Suppression, While
Disulfiram and Sodium Pyrithione Require Both FET3 and CCC2
To check whether the high-affinity iron uptake system is also required for suppression
of vps13∆ by copper sulphate and copper ionophores, we tested their effects on growth
of ccc2∆ vps13∆ and fet3∆ vps13∆ mutant strains on media with SDS. Surprisingly, cop-
per sulphate and elesclomol improved growth of ccc2∆ vps13∆ strain (Figure 6), while
disulfiram and sodium pyrithione were not active. Moreover, we observed a disc-shaped
area of more prominent growth inside the growth zone caused by elesclomol (indicated
on Figure 6). The fact that this area was on the side of copper sulphate application site
indicates positive interaction of elesclomol and copper sulphate in suppression of ccc2∆
vps13∆. To observe the activity of these compounds in the ccc2∆ vps13∆ mutant, higher
concentrations were used than in previous experiments with vps13∆ strain (20× more
than in Figures 1b and 5). Disulfiram and sodium pyrithione were also tested in higher
concentrations (80× more than in Figure 5), but no growth zones were observed (Figure 6).
We noticed also a narrowed growth zone around the filter with copper sulphate at the side
of sodium pyrithione application site (indicated on Figure 6). This suggests an interaction
between copper and sodium pyrithione that negatively affects ccc2∆ vps13∆ growth. When
copper ionophores and copper sulphate were tested on fet3∆ vps13∆ strain, none of them
restored its growth on YPD + SDS medium (Figure 6). This result shows that the high-
affinity iron uptake system is required for suppression of vps13∆ by copper sulphate and
copper ionophores, likewise for CTR1-based suppression. Interestingly, copper sulphate
and elesclomol overcome the lack of CCC2.
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Figure 6. Impact of copper ionophores on the growth of ccc2∆ vps13∆ and fet3∆ vps13∆ cells on YPD + SDS media.
Respective strains were spread onto the plates and substances were spotted on the filter papers. The order of the substances
and concentrations used are indicated. DMSO was used as a negative control. The dashed ellipse in red indicates the
enhanced zone of growth in the border between copper sulphate and elesclomol application. The red arrow indicates the
zone of growth suppression in the border between copper sulphate and sodium pyrithione application.
As mentioned in the previous chapter, the action of copper ionophores in other
diseases models is linked with improvement of mitochondria function. Elesclomol was
shown to improve activity of cytochrome c oxidase (CcO) and rescue respiratory growth
defect of yeast mutants defective in copper metabolism (coa6∆, sco2∆, cox12∆, ctr1∆, atx1∆,
ccs1∆, gsh1∆, ccc2∆, gef1∆), however, not sco1∆ [80]. Sco1 is a copper-binding protein of
mitochondrial inner membrane that delivers copper to the Cox2 subunit of CcO [86,87]
and is required for CcO assembly [88,89]. Therefore the lack of growth improvement of
sco1∆ after elesclomol treatment shows that CcO is a target of elesclomol action [80]. We
confirmed this result and showed that Cox11, another protein delivering copper to CcO
and required for CcO activity [90–93], is also essential for restoring respiratory growth
by elesclomol (Figure 7a). To check if CcO is also relevant for suppression of vps13∆ on
YPD + SDS media, we tested the effect of elesclomol treatment on the growth of cox11∆
vps13∆ and sco1∆ vps13∆ mutants. Growth of both mutants was improved (Figure 7b),
which shows that elesclomol does not require COX11 and SCO1 for suppression of vps13∆.
Moreover, cox11∆ vps13∆ and sco1∆ vps13∆ strains were less sensitive to SDS than vps13∆
(Figure 7b), indicating that switching off CcO actually improves vps13∆ growth. These
results show that CcO activity is not relevant for vps13∆ suppression by elesclomol and is
not required for growth on YPD + SDS media. This also highlights the importance of the
high-affinity iron uptake system for suppression of vps13∆ by copper ionophores.
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Figure 7. Elesclomol does not restore respiratory growth of yeast when CcO is inactivated, but CcO is not relevant for
elesclomol suppression of vps13∆ on YPD + SDS media. (a) cox11∆ and sco1∆ respiratory growth defect is not restored
by elesclomol. Growth of wild type, cox11∆ and sco1∆ strains was compared by a drop test on plates with YPD and
glycerol-containing YPGly and YPGly + elesclomol media in 30 ◦C or 37 ◦C. (b) COX11 and SCO1 are not required for
elesclomol effect on vps13∆ growth on YPD + SDS media. Growth of wild type, vps13∆, cox11∆ vps13∆, and sco1∆ vps13∆
strains was compared by a drop test on plates with YPD, YPD + SDS and YPD + SDS + elesclomol media.
3. Discussion
Ion homeostasis is crucial for proper functioning of all organisms, from unicellular
eukaryotes, such as Saccharomyces cerevisiae yeast, to humans, in which ion imbalance is
associated with many diseases, including neurodegenerative ones. In order to improve
patients’ health, one should understand the mechanisms of these diseases, which would
enable the development of effective therapies. For that, model organisms are used and
studies on them can provide valuable results due to the evolutionary conservation of
cellular mechanisms responsible for ion homeostasis. Here, we showed that defect(s)
observed in the yeast model of VPS13-related diseases can be overcome by overexpression
of CTR1 or CCC2 genes or copper salts addition. We analysed potential mechanisms of
copper-based suppression of vps13∆, and we found that it acts by increasing iron level
via the high-affinity iron uptake system. We investigated functioning of the high-affinity
iron uptake system and found that the levels of its components, Ccc2 and Fet3, which are
required for CTR1-based suppression, were elevated in vps13∆. Finally, we presented three
copper ionophores, that suppressed vps13∆ growth defect, and we showed that they also
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required the functional high-affinity iron uptake system (FET3 and CCC2 genes) for their
action with the exception of elesclomol, which did not require CCC2. Our results point
to the copper-dependent iron uptake as a suppression mechanism of vps13∆ defects and
a potential drug target in VPS13-depenedent diseases (Figure 8). However, we cannot
exclude that other mechanisms may also contribute in vps13∆ suppression.
Figure 8. Schematic representation of the proposed model of copper-based suppression mechanism
of vps13∆ SDS hypersensitivity phenotype. Stress triggered by SDS in the cytoplasm and in the
plasma membrane is suppressed by increased copper uptake either by overexpression of the genes
of the plasma membrane copper transporters Ctr1 or Ctr3, or by treatment with copper ionophores
(ELE—elesclomol; NaPT—sodium pyrithione or DSF—disulfiram). Internalized copper is trans-
ported to the Golgi apparatus by Ccc2 ATPase or by elesclomol, which is also active even in the
absence of Ccc2. Then, copper is incorporated into Fet3 oxidase, which, together with Ftr1 permease,
forms a complex responsible for the high-affinity iron uptake. This complex is transported to the
plasma membrane, where it facilitates iron uptake. Iron is essential for protection against SDS stress
and iron deficiency impairs lipid synthesis, altering the properties and functions of cellular mem-
branes. When copper is abundant in the environment, it could be also directly incorporated into Fet3
localised on the plasma membrane. Another possible (yet not investigated here) putative mechanism
of copper action is its direct impact on complex sphingolipid biosynthesis in Golgi apparatus, which
are important for SDS stress response [57].
Our findings on the CTR1 and CTR3 genes, encoding copper transporters, and copper
sulphate as suppressors of the vps13∆ phenotype turned our attention to the functioning
of copper homeostasis in these cells. In vps13∆, Ctr1–GFP was located at the plasma
membrane, as in wild type cells, but in addition, we observed strong vacuolar GFP signal.
This corresponded well with the western blot analysis that showed similar full-length
Ctr1–GFP levels but more degradation products, including free GFP in vps13∆ cell ex-
tracts as compared with the wild type. This increased degradation of Ctr1–GFP could be
caused by protein trafficking defects observed in vps13∆, such as defects in retromer func-
tioning [43,45,50]. Retromer is possibly required in yeast Ctr1 recycling from endosomes
to plasma membrane, as it was recently documented for Ctr1 in mammalian cells [94].
Decreased recycling can cause increased transport of Ctr1–GFP from endosomes to the
vacuole. The other possibility is that degradation of Ctr1–GFP is increased in vps13∆ cells
due to the elevated copper content. It was shown that Ctr1 is degraded when copper is
abundant [28,29]; therefore, this explanation could also be possible. However, the simplest
mechanism of copper-based suppression of vps13∆ would be by compensating the putative
decrease in copper level. To clarify this contradiction, copper content in wild type and
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mutant cells was studied, and we did not find indication of copper deficiency in the vps13∆
mutant in tested conditions. Moreover, a slight increase in copper content was observed,
which may indicate increased demand for copper and effective copper transport in vps13∆
cells. This also supports the possibility of increased Ctr1–GFP degradation due to the
elevated copper level. One should also keep in mind that copper levels were determined
in yeast grown in YPD media supplemented with copper salt, therefore copper entered
the cell via other transporters than Ctr1 [23]. To conclude this part, we observed increased
degradation of Ctr1–GFP. However, since copper level in vps13∆ is not lowered in tested
conditions, mechanism of CTR1 suppression is rather different than compensating putative
copper deficiency.
Since we did not detect any copper deficiency that could be compensated by increasing
copper transport, another mechanism of copper-related suppression of vps13∆ phenotype
must exist. Based on our previous results regarding the importance of iron for SDS tolerance
in yeast cells [57], we hypothesised that excessive copper can be utilised in Fet3 multicopper
oxidase in order to increase iron uptake and, therefore, improve vps13∆ growth. We
confirmed this by showing that CTR1 overexpression caused an increase in iron levels
in vps13∆ cells and by the fact that FET3 and CCC2 genes were essential for vps13∆
suppression by CTR1. We also showed that overexpression of CCC2 suppresses the growth
defect of vps13∆, but not fet3∆ vps13∆. This suggests that increased iron level in vps13∆
can be also achieved by increasing import of copper to the Golgi apparatus; however, our
iron measurement experiments did not provide solid proof. An increase in iron content in
vps13∆ upon CCC2 overexpression was relatively low (17%, compared to 66% for CTR1)
and did not cross the statistical significance threshold (p = 0.066). The hypothesis that
CCC2 can also act by increasing iron content via the high-affinity iron uptake system was
supported by the fact that FET3 is required for CCC2-based suppression. Moreover, results
of other studies show that deletion of CCC2 causes defective iron uptake [13,95]. Finally,
CCC2 overexpression rescues growth defect in iron-limited conditions of atx1∆ mutant [95],
which is devoid of cytoplasmic Atx1 copper chaperone involved in copper delivery to
Ccc2 [95]. However, other potential non-iron-related mechanisms of CCC2 action may exist.
Addition of copper sulphate greatly increased iron content in cells, showing that copper
alone may act via the same mechanism as copper transporters. When we tested the impact
of CTR1 and CCC2 overexpression on iron levels in vps13∆ cells cultivated in a copper-rich
environment, significant yet moderate increases in iron content (15% and 24% for CTR1
and CCC2, respectively) were observed. Limited effects of CTR1 and CCC2 overexpression
could be explained by achieving high copper saturation of Fet3 oxidase and reaching
activity close to its limit in vps13∆ cells due to the copper supplementation. Therefore,
further increases in intracellular copper by CTR1 overexpression or improving copper
import to the Golgi apparatus by CCC2 overexpression may not greatly influence Fet3
activity and iron uptake in a copper-rich environment. To sum up, we propose that copper
sulphate addition and overexpression of the CTR1 and likely CCC2 genes suppress vps13∆
by increasing iron content in cells. However, it was reported that deletion of CCC2 or FET3
causes copper sensitivity [96,97]; therefore, other putative, non-iron-related, beneficial
effects of increased intracellular copper in vps13∆ cells may be impossible to observe in
ccc2∆ vps13∆ and fet3∆ vps13∆ strains due to the fact of their sensitivity to copper.
Our analysis showed a lower level of iron in the vps13∆ mutant when compared with
wild type cells. This is in agreement with the previous report, in which iron uptake was
decreased in many vps mutants including vps13 [14]. Copper supplementation increased
iron content in vps13∆ cells; however, it was not as effective as it was in the wild type.
When cultivating in YPD media, the iron level in vps13∆ was 74% of the wild type, while
in YPD + CuSO4 it was only 45%. This may suggest partial insufficiency of the high-
affinity iron uptake system in vps13∆. Therefore, we investigated localisation and levels of
protein components of this system: Ccc2 and Fet3. The localisation of Ccc2–GFP and Fet3–
GFP proteins was not altered, but their levels were elevated, which may suggest greater
demand for iron in vps13∆. However, in our previous studies we showed that vps13∆
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was not hypersensitive to ferrozine, an iron chelator limiting iron availability for cells,
and signalling pathways responding to iron deficiencies were not activated in vps13∆ [57].
Moreover, ccc2∆ vps13∆ and fet3∆ vps13∆ double mutants were more sensitive to SDS than
vps13∆, which further implies that the high-affinity iron uptake system is functional in
vps13∆. Perhaps, elevated levels of Ccc2–GFP and Fet3–GFP proteins counteract lower
iron content observed in vps13∆. This decrease in iron level, however, is nowhere near the
iron deficiency observed in the fet3∆ mutant. The fet3∆ cells are hypersensitive to SDS, but
vps13∆ cells are much more so [57]. Therefore, lower iron level may contribute to vps13∆
poor growth on YPD + SDS media only to a small extent, next to previously described
factors potentially related to SDS-hypersensitivity, such as impaired calcium homeostasis,
altered cell wall integrity pathway or sphingolipid biosynthesis [51,57]. To conclude, our
findings did not point to defective functioning of the high-affinity iron uptake system in
vps13∆; however, they suggest its partial insufficiency when copper is abundant.
Surprisingly, contrary to suppression by CTR1 and CCC2, copper sulphate alone was
active in ccc2∆ vps13∆ when a higher concentration was used. In other studies regarding
copper, iron, Ccc2 and Fet3 interplay, it was shown that ccc2∆ is deficient in Fet3 oxidase
activity, which results in impaired iron uptake and respiratory growth [13] and all these
defects of ccc2∆ are reversed by supplementing growth media with copper [13,14,30,63].
It is possible that in ccc2∆ strain Fet3 acquires copper when is in the plasma membrane
from copper-rich environment. This is further supported by the fact, that copper sup-
plementation restores iron uptake in ccc2∆ in Ctr1-independent manner [14]. Therefore,
incorporating environmental copper into Fet3 oxidase localised in the plasma membrane
could be the mechanism in which copper suppress ccc2∆ vps13∆ SDS-hypersensitivity
phenotype. No growth improvement of fet3∆ vps13∆ by copper was observed, which is in
line with cited studies [13,30,63] and with the fact that no iron increase was observed in the
fet3∆ strain upon copper supplementation.
Suppression of the vps13∆ was also achieved by treatment with copper ionophores
and their action required the functional high-affinity iron uptake system. Interestingly,
elesclomol, contrary to disulfiram and sodium pyrithione, was active also in ccc2∆ vps13∆
strain. Observed positive interaction of elesclomol and copper sulphate indicates that
elesclomol activity in ccc2∆ vps13∆ is copper dependent. In other studies, elesclomol was
shown to improve respiratory growth defect of ccc2∆ mutant [80]. Moreover, elesclomol
alleviates defects observed in murine model of Menkes disease [83] in which function
of ATP7A, a homologue of yeast Ccc2, is impaired. These data together with our results
suggest that elesclomol may replace Ccc2 in its function, and transfer copper to the Golgi
apparatus in vps13∆. We also observed that elesclomol was the only drug among copper
ionophores tested, which suppressed vps13∆ canavanine hypersensitivity phenotype, sug-
gesting that this drug may improve endocytosis in vps13∆ or prevent canavanine-related
toxic effects observed in yeast, such as proteotoxic stress [98]. We hypothesised that this is
caused by elesclomol-bound copper ability to enter the Golgi apparatus; however, overex-
pression of CCC2 did not improve vps13∆ growth on media with canavanine (not shown)
indicating that elesclomol may reverse vps13∆ canavanine hypersensitivity growth defect
in the Golgi-independent manner. We also tested the possibility that CcO could be a target
of action of elesclomol, which activities are often linked with mitochondria functioning.
We showed that the COX11 and SCO1 genes, crucial for CcO activity, were not required
for elesclomol suppression of the vps13∆ SDS-hypersensitivity phenotype. Moreover, dele-
tion of these genes improved growth of vps13∆. We hypothesise that switching off CcO
activity, a copper demanding process, may increase a cytoplasmic coper pool, therefore
contributing to growth improvement. Summarising this part, our results show that copper
ionophores suppress vps13∆ and improve its growth on YPD + SDS via the high-affinity
iron uptake system.
While in this work we focused on copper-dependent iron uptake as an vps13∆ sup-
pression mechanism, other copper dependent-mechanisms may exist. An interesting area
for further investigation is the role of Ccc2 in sphingolipid biosynthesis. It was shown
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that cells lacking CCC2 are defective in hydroxylation of complex sphingolipids [99]. Since
elesclomol delivers copper to the Golgi apparatus [83], it may also influence synthesis of
complex sphingolipids. It is still, however, unknown which enzyme is directly responsible
for sphingolipids hydroxylation [100]. Noteworthy, the Sur2 protein required for hydroxy-
lation of ceramides is a diiron enzyme [101], therefore increasing iron content could also
influence complex sphingolipids synthesis. Moreover, CCC2 was originally found as a
cross-complementing gene of calcium sensitivity defect of csg1 mutant [12]. CSG1 encodes
a catalytic subunit of the mannosylinositol phosphorylceramide synthase—an enzyme im-
portant for synthesis of sphingolipids. This further supports Ccc2 impact on sphingolipid
biosynthesis and, perhaps, in some way on calcium signalling. Moreover, in previous
studies, mutants defective in sphingolipid biosynthesis were shown to be hypersensitive to
SDS [57,102]. These results imply that sphingolipid biosynthesis may be a potential target
in improving vps13∆ functioning by copper-dependent mechanism directly or indirectly
by affecting iron level.
To conclude, in this study, we showed that suppression of the vps13∆ SDS-
hypersensitivity phenotype could be achieved by increasing the intracellular copper con-
tent, both in a genetic and pharmacological manner. We showed the importance of the
high-affinity iron uptake system for the mechanism of copper-based suppression. While
the iron system remains functional in vps13∆ cells, we did show some alteration in the
levels of proteins involved in this system. This points to iron homeostasis as an interesting
area for further investigation in higher model organisms of VPS13-related diseases. We
also presented three copper ionophores as drugs effective in our vps13∆ yeast disease
model. The fact that they are known substances, used in treatment for other diseases or are
candidate drugs in ongoing clinical trials, make them particularly interesting for further
testing. If their effectiveness is confirmed in higher model organisms, repurposing of these
drugs will significantly ease their usage in patients, which is crucial especially for treatment
of rare diseases.
4. Materials and Methods
4.1. Strains, Media, and Growth Conditions
The Escherichia coli DH5α strain was used for plasmid propagation. The Saccharomyces
cerevisiae strains used are listed in Table 1. YPD complete medium (1% yeast extract
(Biokar Diagnostics, Allonne, France), 2% tryptone (Biokar Diagnostics), 2% glucose, 1%
adenine), glycerol-containing YPGly (2% glycerol) medium or synthetic complete (SC)
medium (0.067% yeast nitrogen base without amino acids, 2% glucose) with desired
supplementation (amino acids, uracil, adenine, salts, and drugs) were used for yeast
cultivation. For drop tests, cells were grown overnight in respective liquid media, and
cultures were diluted in sterile distilled water to obtain a cell optical density (OD) equal to
OD600∼1. Subsequently, aliquots of 4-fold serial dilutions of cultures were spotted onto
solid media. Plates were incubated at 30 ◦C or 37 ◦C if indicated. Like in our previous
studies [51,57], growth experiments on YPD + SDS plates were performed using several
concentrations of SDS and images were taken after different time of incubation to show
representative results. This approach was necessary because of the high sensitivity of yeast
cells to small changes in the final SDS concentration in the plate, which depends on the lot
of medium and SDS stock as well as other physical factors.
The ccc2∆ vps13∆, fet3∆ vps13∆, cox11∆ vps13∆ and sco1∆ vps13∆ strains were con-
structed using a vps13::URA3 cassette. The cassette was amplified by PCR using pKA475
plasmid (Table 2) as a template. Respective strains were transformed with the cassette and
plated on selective media. Integration was confirmed by PCR.
Strains producing C-terminally GFP-tagged proteins (Ctr1–GFP, Ccc2–GFP, Fet3–GFP)
were constructed according to a previously describe method [103]. The cassettes were
amplified by PCR using pFA6a-GFP(S65T)-kanMX6 (Table 2) as a template. BY4741 and
KJK181A (vps13::URA3) strains were transformed with obtained cassettes and were plated
on selective media. Integrations were confirmed by PCR.
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Table 1. Strains used in this study.
Strain Genotype Source
BY4741 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 Open Biosystem
BYvps13∆ MATa his3∆1 leu2∆0 met15∆0 ura3∆0 vps13::kanMX Open Biosystem
KJK181A MATa his3∆1 leu2∆0 met15∆0 ura3∆0 vps13::URA3 [57]
BYctr1∆ MATa his3∆1 leu2∆0 met15∆0 ura3∆0 ctr1::kanMX Open Biosystem
BYccc2∆ MATa his3∆1 leu2∆0 met15∆0 ura3∆0 ccc2::kanMX Open Biosystem
PS13 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 ccc2::kanMX vps13::URA3 This study
BYfet3∆ MATa his3∆1 leu2∆0 met15∆0 ura3∆0 fet3::kanMX Open Biosystem
PS14 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 fet3::kanMX vps13::URA3 This study
BYcox11∆ MATa his3∆1 leu2∆0 met15∆0 ura3∆0 cox11::kanMX Open Biosystem
PS5 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 cox11::kanMX vps13::URA3 This study
BYsco1∆ MATa his3∆1 leu2∆0 met15∆0 ura3∆0 sco1::kanMX Open Biosystem
PS6 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 sco1::kanMX vps13::URA3 This study
PS7 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 CTR1-GFP::kanMX This study
PS8 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 CTR1-GFP::kanMX vps13::URA3 This study
PS9 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 CCC2-GFP::kanMX This study
PS10 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 CCC2-GFP::kanMX vps13::URA3 This study
PS11 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 FET3-GFP::kanMX This study
PS12 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 FET3-GFP::kanMX vps13::URA3 This study
Table 2. Plasmids used in this study.
Plasmid Source
pYEp181lac [104]







pRS415-SEC7-mRFP This study, restricted
pKA475 (vps13∆::URA3) [57]
4.2. Plasmids
The plasmid used are listed in Table 2. pFL44-CTR3, containing the CTR3 gene and
fragments of the VIP1 and BER1 genes was isolated from the pFL-44 genomic bank [61]
in our screen for multicopy suppressors of vps13-I2749R [51]. pYEp181lac-CTR3 was
obtained by amplifying the CTR3 gene by PCR using pFL44-CTR3 as a template and
ligation of the PCR product to pYEp181lac digested with EcoRI and BamHI restriction
enzymes. pYEp181lac-CTR1 and pYEp181lac-CCC2 were obtained by amplifying the CTR1
and CCC2 genes by PCR using genomic DNA as a template and subsequent ligation of the
PCR products to YEp181lac digested with HindIII and PstI restriction enzymes for CTR1
and XbaI, and EcoRI for CCC2.
pRS415-SEC7-mRFP was obtained by transferring fragment from pRS316-SEC7-mRFP
to pRS415 using BamHI and XhoI restriction enzymes.
4.3. Copper and Iron Measurements
Our protocol was adapted based on previously used approaches [108]. Briefly, the
BY4741 and vps13∆ (KJK181A) yeast strains, bearing empty vector or plasmid express-
ing the CTR1 or CCC2 genes, were grown for 24 h in YPD + 0.25 mM CuSO4 for copper
measurement and in YPD or YPD + 0.25 mM CuSO4 for iron measurement. Copper sup-
plementation was required to observe results above copper levels in blank samples. After
cultivation, cells were collected and washed once with 10 mM EDTA (ethylenediaminete-
traacetic acid) and three times with metal-free water. Next, 16 OD of yeast cells (measured
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after washing) was digested in 95 ◦C for 24 h in 10% ultrapure nitric acid (HNO3) with
occasional mixing. Digestion products were diluted 4 times with metal-free water and
subsequently measured by inductively coupled plasma atomic emission spectroscopy
(ICP-AES). Measurements were performed commercially in Laboratório de Análises at Uni-
versidade Nova de Lisboa (Department of Chemistry, Faculdade de Ciências e Tecnologia,
Universidade Nova de Lisboa, 2829-516 Caparica, Portugal). Data were processed and
visualized in Python (3.6.4, https://www.python.org/, accessed on 14 October 2020) using
Pandas (1.0.1, The pandas development team, https://zenodo.org/record/3644238#.YDK
vquhKg2w, accessed on 14 October 2020) and Seaborn (0.11.0, Michael Waskom and the
seaborn development team, https://zenodo.org/record/4019146#.YDKwNuhKg2x, ac-
cessed on 14 October 2020) libraries. Statistical analysis was performed with R (Rcmdr, 2.6–2,
https://www.rcommander.com/, accessed on 14 October 2020).
4.4. Drug Tests
Drug tests were performed as described previously [57,109], with the exception for
the canavanine hypersensitivity phenotype, where yeast were cultivated in SC –arg media
to exponential phase prior spreading on SC –arg + canavanine plate. Briefly, cells were
spread onto plates with the desired solid media, sterile paper filters were placed on
the surface of the media, and drugs were applied on filters. Originally, disulfiram was
identified as an active drug from Prestwick Chemical Library (Prestwick Chemical, Illkirch-
Graffenstaden, France; last used 04.2017). In the presented work, drugs were used from
the undermentioned sources: disulfiram, sodium pyrithione, bathocuproinedisulfonic
acid disodium salt, and ferrozine (Sigma–Aldrich, St. Louis, MO, USA), and elesclomol
(MedChemExpress, Monmouth Junction, NJ, USA).
4.5. Fluorescence Microscopy
For fluorescence microscopy of cells producing Ctr1–GFP protein, yeast were grown
in YPD for 24 h and were stained with CMAC (7-amino-4-chloromethylcoumarin) for
30 min prior to observation. For fluorescence microscopy of cells producing Ccc2–GFP
and Fet3–GFP proteins, yeast were grown in SC –leu + 0.25 mM ferrozine (an iron chelator
limiting iron availability for cells) to early exponential phase (5 h of cultivating). Strains
expressing genomic copy of CCC2–GFP were transformed with plasmid encoding Sec7–RFP.
For the Fet3–GFP localization studies, strains with GFP-tagged Fet3 were transformed with
empty vector. Cells were viewed with an Eclipse E800 (Nikon, Tokyo, Japan) fluorescence
microscope equipped with a DS-5Mc camera (Nikon, Tokyo, Japan). Images were collected
using Lucia General 5.1 software (Laboratory Imaging Ltd., Prague, Czech Republic). The
same fields were viewed by differential interference contrast (DIC) optics.
4.6. Western Blotting
For western blotting, yeast were grown in the same conditions as for fluorescence
microscopy: 24 h in YPD for strains with Ctr1–GFP and 5 h in SC –leu for strains (bearing
empty vector) with Ccc2–GFP and Fet3–GFP. After cultivation, cells were disrupted with
glass beads (0.5 mm) in 2x Thorner buffer and incubated in 37 ◦C for 10 min. Samples were
analysed by SDS-PAGE followed by western blotting using anti-GFP (1:4000, Roche, Basel,
Switzerland), anti-Pgk1 (1:20,000, Thermo Fisher Scientific, Waltham, MA, USA) and anti-
mouse horseradish peroxidase (HRP)-conjugated (1:4000, Jackson ImmunoResearch, Balti-
more Pike, PA, USA) antibodies. Blots were developed using Pierce™ enhanced chemilumi-
nescence (ECL) Western Blotting Substrate (Thermo Fisher Scientific, Waltham, MA, USA),
except for Ccc2–GFP protein, where Amersham™ ECL™ Prime Western Blotting Detection
Reagent (GE Healthcare, Chicago, IL, USA) was used. Densitometry was performed with
ImageJ (https://imagej.nih.gov/ij/, accessed on 14 October 2020). Data were processed
and visualized in Python (3.6.4, https://www.python.org/, accessed on 14 October 2020)
using Pandas (1.0.1, The pandas development team, https://zenodo.org/record/3644238#
.YDKvquhKg2w, accessed on 14 October 2020) and Seaborn (0.11.0, Michael Waskom and
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the seaborn development team, https://zenodo.org/record/4019146#.YDKwNuhKg2x,
accessed on 14 October 2020) libraries. Statistical analysis was performed with R (Rcmdr,
2.6–2, https://www.rcommander.com/, accessed on 14 October 2020).
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Appendix A
Figure A1. The vps13∆ is not sensitive to bathocuproinedisulfonic acid disodium salt (BPS) and
copper-based suppression is not specific to vps13∆. (a) Growth of wild type, vps13∆ and ctr1∆ strains
was compared by a drop test on plates with YPD and YPD + BPS media. (b) Growth of wild type
and vps13∆ strains was compared by a drop test on plates with YPD, YPD + SDS and YPD + SDS +
CuSO4 media. (c) Impact of CTR1 overexpression on wild type cells growth was investigated by a
drop test on plates with YPD and YPD + SDS media.
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Figure A2. CTR1 overexpression suppresses vps13∆ hypersensitivity to cadmium and very weakly
suppresses hypersensitivity to canavanine. Growth of wild type and vps13∆ strains bearing plasmid
with CTR1 gene or empty vector was compared by a drop test on plates with YPD, YPD + CdCl2 and
SC –arg + canavanine media.
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